[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UA94074C2 - Производные диоксолана для лечения рака - Google Patents

Производные диоксолана для лечения рака

Info

Publication number
UA94074C2
UA94074C2 UAA200808913A UAA200808913A UA94074C2 UA 94074 C2 UA94074 C2 UA 94074C2 UA A200808913 A UAA200808913 A UA A200808913A UA A200808913 A UAA200808913 A UA A200808913A UA 94074 C2 UA94074 C2 UA 94074C2
Authority
UA
Ukraine
Prior art keywords
treatment
dioxolane
derivates
cancer
compounds
Prior art date
Application number
UAA200808913A
Other languages
English (en)
Ukrainian (uk)
Inventor
Фінн Мірен
Саннволл Маріт Ліланн
Стейнар Хаген
Олє Хенрік Еріксен
Original Assignee
Клавіс Фарма Ас
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Клавіс Фарма Ас filed Critical Клавіс Фарма Ас
Publication of UA94074C2 publication Critical patent/UA94074C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Это изобретение касается некоторых производных ненасыщенных жирных кислот терапевтически активных 1,3-диоксоланнуклеозидных аналогов и фармацевтических препаратов, которые их содержат. Упомянутые производные упоминаются в заявке как «Соединения формулы (I)». Соединения формулы (I) могут применяться для лечения раковых заболеваний. Также включается лечение как твердых опухолей, так и гематологического рака, такого как лейкемии, лимфомы и множественные миеломы. EMBED ISISServer (I)
UAA200808913A 2005-12-08 2006-12-07 Производные диоксолана для лечения рака UA94074C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO20055841A NO324263B1 (no) 2005-12-08 2005-12-08 Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser

Publications (1)

Publication Number Publication Date
UA94074C2 true UA94074C2 (ru) 2011-04-11

Family

ID=35539185

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200808913A UA94074C2 (ru) 2005-12-08 2006-12-07 Производные диоксолана для лечения рака

Country Status (14)

Country Link
US (2) US20070135436A1 (ru)
EP (1) EP1968971B1 (ru)
JP (1) JP5185823B2 (ru)
KR (1) KR101425228B1 (ru)
AU (1) AU2006323278B2 (ru)
CA (1) CA2632280A1 (ru)
IL (1) IL191981A0 (ru)
NO (1) NO324263B1 (ru)
NZ (1) NZ569140A (ru)
RU (1) RU2418795C2 (ru)
TW (1) TWI382978B (ru)
UA (1) UA94074C2 (ru)
WO (1) WO2007067071A1 (ru)
ZA (1) ZA200805522B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497292B2 (en) 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
US8399420B2 (en) * 2007-09-26 2013-03-19 Mount Sanai School of Medicine Azacytidine analogues and uses thereof
GB201006181D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3100478A1 (de) 1981-01-09 1982-08-12 Dr. Thilo & Co GmbH, 8021 Sauerlach 5'ester von pyrimidinnucleosiden mit antiviraler wirksamkeit, verfahren zur herstellung und daraus hergestellte arzneimittel
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
IE980216A1 (en) 1989-04-17 2000-02-23 Scotia Holdings Plc Anti-virals
DE4026265A1 (de) 1990-08-20 1992-02-27 Boehringer Mannheim Gmbh Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
US5444063A (en) 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB2260319B (en) * 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
GB9307043D0 (en) * 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
GB9515279D0 (en) * 1995-07-25 1995-09-20 Norsk Hydro As Improved therapeutic agents
AU7954694A (en) * 1993-09-10 1995-03-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis b virus activity
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
DE19505168A1 (de) * 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
JP4413996B2 (ja) * 1995-06-07 2010-02-10 エモリー・ユニバーシティ 抗ｂ型肝炎ウィルス活性を有するヌクレオシド
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
HU224918B1 (en) * 1997-01-24 2006-04-28 Conpharma As Gemcitabine derivatives, process for their preparation and pharmaceutical compositions containing them
GB2321455A (en) 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
WO1999026958A1 (en) 1997-11-25 1999-06-03 Protarga, Inc. Nucleoside analog compositions and uses thereof
AU7361400A (en) 1999-09-08 2001-04-10 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
US6526033B1 (en) * 1999-09-17 2003-02-25 Lucent Technologies Inc. Delivering calls to GSM subscribers roaming to CDMA networks via IP tunnels
US6670341B1 (en) * 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
EP1225899A2 (en) * 1999-11-04 2002-07-31 Virochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
CN100376570C (zh) * 2000-10-13 2008-03-26 希拉生物化学股份有限公司 改善胞间传输的二氧戊环类似物
US20050090659A1 (en) 2001-11-21 2005-04-28 Dieter Herrmann Phospholepid derivatives of nucleosides as antitumaorl medicaments

Also Published As

Publication number Publication date
AU2006323278A1 (en) 2007-06-14
NO20055841D0 (no) 2005-12-08
US20100062996A1 (en) 2010-03-11
KR101425228B1 (ko) 2014-08-06
EP1968971A4 (en) 2012-01-25
ZA200805522B (en) 2009-04-29
RU2418795C2 (ru) 2011-05-20
EP1968971B1 (en) 2013-03-27
TW200728296A (en) 2007-08-01
JP5185823B2 (ja) 2013-04-17
EP1968971A1 (en) 2008-09-17
US8349834B2 (en) 2013-01-08
KR20080086481A (ko) 2008-09-25
IL191981A0 (en) 2008-12-29
AU2006323278B2 (en) 2012-08-09
NO324263B1 (no) 2007-09-17
TWI382978B (zh) 2013-01-21
US20070135436A1 (en) 2007-06-14
JP2009518393A (ja) 2009-05-07
RU2008127495A (ru) 2010-01-20
NO20055841L (no) 2007-06-11
NZ569140A (en) 2010-07-30
WO2007067071A1 (en) 2007-06-14
CA2632280A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
ES2437917T3 (es) Nuevos nucleósidos de 7-desazapurina para usos terapéuticos
EA201490477A1 (ru) Фармацевтические составы, содержащие пропиленгликоль-гидрат дапаглифлозина
SI1819227T1 (sl) Farmacevtska formulacija decitabina
MX2007008924A (es) Compuestos quimicos.
NZ553405A (en) Nucleoside phosphonate conjugates as anti-HIV agents
SG148177A1 (en) Novel cis-imidazolines
TW200634003A (en) Chemical compounds
WO2005039498A3 (en) Methods of treating cancer with hdac inhibitors
TW200616974A (en) Chemical compounds
ECSP066452A (es) Métodos para el tratamiento del cáncer con inhibidores de hdac
YU44404A (sh) Postupak za identifikovanje ciljnih enzima tumora
MX2010007523A (es) Nuevos derivados de pirazolo[3,4-d]pirimidina como farmacos anticancer.
NZ702159A (en) Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
HK1120427A1 (en) Anti-glypican-3 antibody
HK1065707A1 (en) 4--substituted nucleosides
TNSN07322A1 (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
IL179671A0 (en) 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido[2,3-d]pyrimidine derivatives and pharmaceutical compositions containing the same
TW200736234A (en) Chemical compounds
EP1962843A4 (en) USE OF PARP-1 INHIBITORS
WO2008154083A3 (en) Compounds, compositions and methods for the treatment of synucleinopathies
MX2007013624A (es) Inhibidores de proteina cinasa.
WO2008105852A3 (en) Mucoadhesive nanoparticles for cancer treatment
TW200716204A (en) Pharmaceutical composition
UA90893C2 (ru) Пероральная дозированная форма производных гемцитабина
MY143549A (en) Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases